

CURRICULUM VITAE

Bert Martin Glaser, M.D.

Address: Offices: 901 Dulaney Valley Road
Suite 200
Towson, MD 21204-0603

8065 Leesburg Pike
Suite 160
Vienna, VA 22182-2738

Positions Held

- 11/07/2008- present President, Society for Excellence in Eyecare
- 12/16/2003-11/2008 Secretary, Society for Excellence in Eyecare
- 07/2003 – present Board of Directors, Society for Excellence in Eyecare
- 3/89—Present Executive Director
The Bert M. Glaser National Retina Institute
Towson/Chevy Chase, Maryland
Vienna, Virginia
- 9/2001-06/04 Clinical Professor of Ophthalmology
The George Washington University
Medical Center
Washington, D.C.
- 7/97—4/98 Chairman
Pioneer EyeCare
Baltimore, Maryland
- 8/94—7/97 President
Pioneer EyeCare
Baltimore, Maryland
- 7/1/88—6/30/91 Professor of Ophthalmology
Wilmer Ophthalmological Institute
Johns Hopkins University School of Medicine
Baltimore, Maryland
(Clinical Specialty: Vitreoretinal Surgery)

5/85—5/86	W. Barry Wood Fellow in Molecular Biology and Genetic Engineering Johns Hopkins University Baltimore, Maryland
2/84—6/88	Associate Professor of Ophthalmology Wilmer Ophthalmological Institute Johns Hopkins University School of Medicine Baltimore, Maryland
7/81—1/84	Assistant Professor of Ophthalmology Wilmer Ophthalmological Institute Johns Hopkins University School of Medicine Baltimore, Maryland
7/81-3/89	Director, Center for Vitreo-retinal Research Wilmer Ophthalmological Institute Johns Hopkins University School of Medicine Baltimore, Maryland

Professional Societies

1979—Present	Member — The Association for Research in Vision and Ophthalmology
1981—Present	Member — American Academy of Ophthalmology
1981—unknown	Member — American Association for the Advancement of Science
1981—1985	Member — NIH Behavioral & Neurosciences Study Section, Subcommittee 2
1982—2004	Active Fellow — Pan-American Association of Ophthalmology
1984—Present	Member — The Macula Society
1986—unknown	Member — Federation of American Societies for Experimental Biology
1987—Present	Member — The American Society of Retina Specialists (formerly The Vitreous Society)
1988—unknown	Member — The American Society for Cell Biology
1990—Present	Member — Club Jules Gonin

1992—unknown Member — Maryland Society of Eye Physicians and Surgeons

2003-Present Member- Society for Excellence in EyeCare

Education

1966—1970 New York University
New York
Degree — B.S.
Majors — Physics and Mathematics

1970—1972 Columbia University
New York
Postgraduate Studies in Physics

1972—1976 Columbia University
College of Physicians and Surgeons
New York
Degree — M.D.

1976—1977 Johns Hopkins Hospital
Intern, Internal Medicine

7/77—6/80 Johns Hopkins Hospital
Baltimore, Maryland
Resident, Ophthalmology

7/80—12/80 Johns Hopkins Hospital
Baltimore, Maryland
Fellowship in Diseases & Surgery of the Retina and Vitreous

1/81—6/81 Johns Hopkins Hospital
Baltimore, Maryland
Chief Resident, Ophthalmology

Honors

1976 Alpha Omega Alpha Honor Medical Society, Columbia University

1976 Alvin Behren's Memorial Award for Excellence in
Ophthalmology,
Columbia University

- 1979 **Dean’s Award for Distinguished Research in Medicine,**
The Johns Hopkins University
- 1979 **Meyer’s Honor Award for Distinguished Research in Ophthalmology,**
The Johns Hopkins University and Hospital
- 1982 Research to Prevent Blindness **Manpower Award**
- 1983 Research to Prevent Blindness **Olga Keith Weiss Research**
Scholars Award
- 1989 **Cogan Award & Cogan Lecturer** — Annual Meeting of The
Association for Research in Vision and Ophthalmology, Sarasota,
Florida, May 1989
- 1990 University of California School of Medicine
Certificate of Appreciation for Contributions, Outstanding
Achievements, and Dedicated Service
Visiting Professor
- 1991 **Rosenthal Award in the Visual Sciences** (through
The Macula Society)
- 1991 **Award of Merit in Retina Research** from the Retina
Research Foundation
- 1995-96 Selected for Honor Member in the National Directory of “*Who’s*
Who” for 1995-1996
- 2001 **Senior Honor Award** from the Vitreous Society
- 2005 **Senior Honor Award** from the American Society of Retina Specialists

Research Grants

- 1984-1987 Grant #83-12-29-01 Randomized Study of Silicone Oil in
Patients With Proliferative Vitreoretinopathy (PVR)
- 1985-1987 Grant #85-07-18-02 Cryotherapy for Retinopathy of Prematurity
- 1986-1988 Grant #EY06888-01 Microscopic Examination of Vessel
Regression In Vivo
- 1986-1988 Grant #EY05922-01 Angiogenic Retinal Extract Enhances

Prostacyclin Release

1986-1988	Grant #1RO1HL38900-01 Analysis of Capillary-like Cell Aggregates In Vitro.
1986-1988	Juvenile Diabetes Foundation, Inhibition of Neovascularization by Substances Derived from Pig RPE after Pan-Retinal Photocoagulation
1988-1990	NIH Grant — Control of Retinal Microvascular Endothelial Cell Growth
1987-1989	Grant #EYO7104-01 Experimental Traction Retinal Detachment
1987-1988	Fight for Sight Grant #87063
1988-1989	Eye Disorder Case Control Studies NIH Grant #EY-87-12

Editorial Boards

01/1988 – 12/1992	Investigative Ophthalmology & Visual Science
? ?	Retina: The Journal of Retinal & Vitreous Diseases

Advisory Boards

02/2006-present	Scientific Advisory Board, ScienceBased Health
1989-1993	Scientific Advisory Board Helen Keller Eye Research Foundation

Research Fellows

Funding

1981—1982	Jesus Vidaurri-Leal Director, Eye Hospital Ophthalmological Instituto Monterrey, Mexico	Mexican Government
1982—1983	Peter A. Campochiaro Assistant Professor University of Virginia	Private

1983—1985	Misao Sato Nihon University Tokyo, Japan	University of Tokyo Tokyo, Japan
1983—1985	Sheri L. Rowen Residency Program University of Maryland	National Eye Institute
1984—1985	Karl Golnik Residency Program University of Virginia	Johns Hopkins University Training Grant
1984—1986	Gary H. Cassel Assistant Professor Johns Hopkins University	National Eye Institute
1984—1986	Marcos Lemor Residency Program White Memorial Hospital	Juvenile Diabetic Foundation
1985—1986	Arvind Singh Aberdeen Royal Infirmary Scotland	Aberdeen Royal Infirmary
1986—1987	Robert L. Avery	Johns Hopkins University Training Grant
1986—1988	Laurie Kuwashima	National Eye Institute
1986—1987	Elisha Bartov	Stein Foundation
1986—1987	Thomas Connor, Jr.	Johns Hopkins University Training Grant
1986—1987	Hideyuki Hayashi	Private — Fukuoka University, Fukuoka, Japan
1987—1988	Mary Lansing	NIH Training Grant
1987—1988	Steve Resnick	Private
1987—1988	Mathew MacCumber	Johns Hopkins University Training Grant
1987—1988	Alfred Covington	Johns Hopkins University Training Grant

1987—1987	Hitoshi Kato	Private — Fukuoka University, Fukuoka, Japan
1987—1988	Timothy Tom	Private
1988—1989	Ingrid Adamsons	Johns Hopkins University Training Grant
1988—1989	Louis Giavedoni	University of Canada
1988—1989	Mathew MacCumber	Johns Hopkins University Training Grant
1988—1989	Joseph Moisseiev	Stein Foundation
1988—1989	Thierry Delayre	Private
1991—	Takashi Nonaka	Fukuoka University Fukuoka, Japan
1991—1993	Raul A. Pena	Private

Named Lectureships

Cogan Lecture (Annual Meeting of The Association for Research in Vision and Ophthalmology, Sarasota, Florida, May 1989)

Broadhurst Lecture, "Cell Biology of Proliferative Retinal Disorders" (Eye Research Institute, Boston, MA, October 12, 1989)

The LuEsther T. Mertz Vitreous-Retina-Macula Lecture (Manhattan Eye, Ear, and Throat Hospital, New York City, October 1990)

Charles L. Schepens Lecture (24th Annual Meeting of the Retina Society, Quebec City, Canada, September 1991)

The Ronald G. Michels Memorial Lecture (2nd Annual Meeting of the Atlantic Vitreoretinal Surgery Study Group, Baltimore, Maryland, November 1991)

Publications

1. Morishima H, Glaser BM, Nieman W, and James LS: Effect of hyperthermia on uterine activity and on the fetus. Am J Obst & Gyn 121:531-538, 1975.
2. Lee C, Katz RL, Lee ASJ, and Glaser BM: A new instrument for continuous recording of the evoked compound electromyogram in the clinical setting. Anesth Analog 56:260-270, 1977.
3. Glaser BM, D'Amore PA, Michels RG, Patz A, and Fenselau A: Demonstration of vasoproliferative activity from mammalian retina. J Cell Biol 84:298-304, 1980.
4. Glaser BM, D'Amore PA, Michels RG, Brunson SK, Fenselau AH, Rice T, and Patz A: The demonstration of angiogenic activity from ocular tissues: Preliminary Report. Ophthalmology 87:440-446, 1980.
5. Glaser BM, D'Amore PA, Seppa H, Seppa S, and Schiffmann E: Adult tissues contain chemoattractants for vascular endothelial cells. Nature 288:483-484, 1980.
6. Glaser BM, D'Amore PA, Luttly GA, Fenselau AH, Michels RG, and Patz A: Chemical mediators of intraocular neovascularization. Trans Ophthal Soc. U.K. 100:369-373, 1980.
7. Glaser BM, D'Amore PA, and Michels RG: The effect of human intraocular fluid on vascular endothelial cell migration. Ophthalmology 88:986-991, 1981.
8. D'Amore PA, Glaser BM, Brunson SK, and Fenselau AH: Angiogenic activity from bovine retina: Partial purification and characterization. Proc Natl Acad Sci 78:3068-3072, 1981.

9. Seppa S, Seppa H, Liotta LA, Glaser BM, Martin GR, and Schiffman E: Cultured tumor cells produce chemotactic factors specific for endothelial cells: A possible mechanism for tumor-induced angiogenesis. Invasion and Metastasis 3:139-150, 1983.
10. Glaser BM: Relationship of cataract extraction and rubeosis in diabetes mellitus. Ophthalmology 90:819-820, 1983.
11. Kalebic T, Garbisa S, Glaser B, and Liotta LA: Basement membrane collagen: Degradation by migrating endothelial cells. Science 221:281-283, 1983.
12. Gonzalez RG, Chang HM, Barnett P, Aguayo J, Glaser B, Rosen B, Burt CT, and Brady T: Nuclear magnetic resonance imaging of the vitreous body. Science 223:399-400, 1984.
13. Smiddy WE, Fine SL, Green WR, and Glaser BM: Clinicopathologic correlation of krypton red, argon blue-green, and argon green laser photocoagulation in the human fundus. Retina 4:15-21, 1984.
14. Thompson JT and Glaser BM: Effect of lensectomy on the movement of tracers from vitreous to aqueous. Arch Ophthalmol 102:1077-1078, 1984.
15. Vidaurri-Leal J, Hohman R, and Glaser BM: Effect of vitreous on morphologic characteristics of retinal pigment epithelial cells: A new approach to the study of proliferative vitreoretinopathy. Arch Ophthalmol 102:1220-1223, 1984.
16. Vidaurri-Leal JS and Glaser BM: Effect of fibrin on morphologic characteristics of retinal pigment epithelial cells. Arch Ophthalmol 102:1376-1379, 1984.
17. Campochiaro PA, Jerdan JA, and Glaser BM: Serum contains chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol 102:1830-1833, 1984.
18. Glaser BM, deBustros S, and Michels RG: Postoperative retinal breaks occurring after intravitreal silicone oil injection. Retina 4:246-248, 1984.
19. Campochiaro PA and Glaser BM: Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch Ophthalmol 103:576-579, 1985.
20. de Bustros S, Glaser BM, Michels RG, and Auer C: Effect of epsilon-aminocaproic acid on postvitrectomy hemorrhage. Arch Ophthalmol 103:219-221, 1985.
21. Thompson JT and Glaser BM: Role of lensectomy and posterior capsule in movement of tracers from vitreous to aqueous. Arch Ophthalmol 103:420-421, 1985.
22. Campochiaro PA, Kaden IH, Vidaurri-Leal J, and Glaser BM: Cryotherapy enhances intravitreal dispersion of viable retinal pigment epithelial cells. Arch Ophthalmol 103:434-436, 1985.
23. Aguayo J, Glaser B, Mildvan A, Cheng H-M, Gonzalez RG, and Brady T: Study of

- vitreous liquifaction by NMR spectroscopy and imaging. Invest Ophthalmol Vis Sci 26:692-697, 1985.
24. de Bustros S, Glaser BM, and Johnson MA: Thrombin infusion for the control of intraocular bleeding during vitreous surgery. Arch Ophthalmol 103:837-839, 1985.
 25. Rowen SL and Glaser BM: Retinal pigment epithelial cells release a chemoattractant for astrocytes. Arch Ophthalmol 103:704-707, 1985.
 26. Schachat AP and Glaser BM: Retinal hamartoma, acquired retinoschisis, and retinal hole. Am J Ophthalmol 99:604-605, 1985.
 27. McDonnell PJ, Rowen SL, Glaser BM, and Sato M: Posterior capsule opacification: An in vitro model. Arch Ophthalmol 103:1378-1381, 1985.
 28. Campochiaro PA, Jerdan JA, Glaser BM, Cardin A, and Michels RG: Vitreous aspirates from patients with proliferative vitreoretinopathy stimulate retinal pigment epithelial cell migration. Arch Ophthalmol 103:1403-1405, 1985.
 29. Campochiaro PA and Glaser BM: Endothelial cells release a chemoattractant for retinal pigment epithelial cells in vitro. Arch Ophthalmol 103:1876-1880, 1985.
 30. Glaser BM, Campochiaro PA, Davis JL Jr, and Sato M: Retinal pigment epithelial cells release an inhibitor of neovascularization. Arch Ophthalmol 103:1870-1875, 1985.
 31. Yeo JH, Sadeghi J, Campochiaro PA, Green WR, and Glaser BM: Intravitreal fibronectin and platelet-derived growth factor: New model for traction retinal detachment. Arch Ophthalmol 104: 417-421, 1986.
 32. Jerdan JA, Michels RG, and Glaser BM: Diabetic preretinal membranes: An immunohistochemical study. Arch Ophthalmol 104: 286-290, 1986.
 33. Campochiaro PA and Glaser BM: Mechanisms involved in retinal pigment epithelial cell chemotaxis. Arch Ophthalmol 104:277-280, 1986.
 34. Thompson JT, Glaser BM, Michels RG, and de Bustros S: The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology 93:279-282, 1986.
 35. Thompson JT, Auer CL, de Bustros S, Michels RG, Rice TA, and Glaser BM: Prognostic indicators of success and failure in vitrectomy for diabetic retinopathy. Ophthalmology 93:290-295, 1986.
 36. Campochiaro PA and Glaser BM: A retina-derived stimulator(s) of retinal pigment epithelial cell and astrocyte proliferation. Exp Eye Research 43:449-457, 1986.
 37. Singh AK, Glaser BM, Lemor M, and Michels RG: Gravity-dependent distribution of retinal pigment epithelial cells dispersed into the vitreous cavity. Retina 6:77-80, 1986.

38. Lemor M, de Bustros S, and Glaser BM: Low-dose colchicine inhibits astrocyte, fibroblast, and retinal pigment epithelial cell migration and proliferation. Arch Ophthalmol 104:1223-1225, 1986.
39. Lemor M, Yeo JH, and Glaser BM: Oral colchicine for the treatment of experimental traction retinal detachment. Arch Ophthalmol 104:1226-1229, 1986.
40. Glaser BM: Treatment of giant retinal tears combined with proliferative vitreoretinopathy. Ophthalmology 93:1193-1197, 1986.
41. Avery RL and Glaser BM: Inhibition of retinal pigment epithelial cell attachment by a synthetic peptide derived from the cell-binding domain of fibronectin. Arch Ophthalmol:104 1220-1222, 1986.
42. Campochiaro PA, Jerdan JA, and Glaser BM: The extracellular matrix of human retinal pigment epithelial cells in vivo and its synthesis in vitro. Invest Ophthalmol Vis Sci 27:1615-1621, 1986.
43. Singh AK, Michels RG, and Glaser BM: Scleral indentation following cryotherapy and repeat cryotherapy enhance release of viable retinal pigment epithelial cells. Retina 6:176-178, 1986.
44. Yeo JH, Vidaurri-Leal J, and Glaser BM: Extension of retinal detachments as a complication of pneumatic retinopathy. Arch Ophthalmol 104:1161-1163, 1986.
45. Thompson JT, de Bustros S, Michels RG, Rice TA, and Glaser BM: Results of vitrectomy for proliferative diabetic retinopathy. Ophthalmology 93:1571-1574, 1986.
46. Jerdan JA and Glaser BM: Retinal microvessel extracellular matrix: an immunofluorescent study. Invest Ophthalmol Vis Sci 27:194-203, 1986.
47. Yeo JH, Glaser BM, and Michels RG: Silicone oil in the treatment of complicated retinal detachments. Ophthalmology 94: 1109-1113, 1987.
48. Smiddy WE, Stark WJ, Michels RG, Maumenee AE, Terry AC, and Glaser BM: Cataract extraction after vitrectomy. Ophthalmology 94:483-487, 1987.
49. Smith PW, Stark WJ, Maumenee AE, Enger CL, Michels RG, Glaser BM, and Bonham RD: Retinal detachment after extracapsular cataract extraction with posterior chamber intraocular lens. Ophthalmology 94:495-504, 1987.
50. Glaser BM, Cardin A, and Biscoe B: Proliferative vitreoretinopathy: The mechanism of development of vitreoretinal traction. Ophthalmology 94:327-332, 1987.
51. Glaser BM, Campochiaro PA, Davis JL Jr, and Jerdan JA: Retinal pigment epithelial cells release inhibitors of neovascularization. Ophthalmology 94:780-784, 1987.
52. Glaser BM: The use of intravitreal thrombin to control hemorrhage during retinectomy. Retina 8:1-2, 1988.

53. de Bustros S, Thompson JT, Michels RG, Enger C, Rice TA, and Glaser BM: Nuclear sclerosis after vitrectomy for idiopathic epiretinal membranes. Am J Ophthalmol 105:160-164, 1988.
54. Del Priore LV, Glaser BM, Quigley HA, Dorman ME, and Green WR: Morphology of pig retinal pigment epithelium maintained in organ culture. Arch Ophthalmol 106:1286-1290, 1988.
55. Glaser BM and The Silicone Study Group: Silicone oil for proliferative vitreoretinopathy: Does it help or hinder? Arch Ophthalmol 106:323-324, 1988.
56. Isernhagen RD, Michels RG, Glaser BM, de Bustros S, and Enger C: Hospitalization requirements after vitreoretinal surgery. Arch Ophthalmol 106:767-770, 1988.
57. Smiddy WE, Isernhagen RD, Michels RG, Glaser BM, and de Bustros SN: Vitrectomy for nondiabetic vitreous hemorrhage: Retinal and choroidal vascular disorders. Retina 8:88-95, 1988.
58. Isernhagen RD, Smiddy WE, Michels RG, Glaser BM, and de Bustros S: Vitrectomy for nondiabetic vitreous hemorrhage not associated with vascular disease. Retina 8:81-87, 1988.
59. Smiddy, WE, Michels RG, Glaser BM, and de Bustros S: Vitrectomy for macular traction caused by incomplete vitreous separation. Arch Ophthalmol 106:624-628, 1988.
60. Smiddy WE, Michels RG, Glaser BM, and de Bustros S: Vitrectomy for impending idiopathic macular holes. Am J Ophthalmol 105:371-376, 1988.
61. Glaser BM: Extracellular modulating factors and the control of intraocular neovascularization. An Overview. Arch Ophthalmol 106:603-607, 1988.
62. Bartov E, Jerdan JA and Glaser BM: A simple technique for isolating pure cell populations from mixed primary cultures. J Tissue Culture Methods 11:181-183, 1988.
63. de Bustros S, Rice TA, Michels RG, Thompson JT, Marcus S, and Glaser BM: Vitrectomy for macular pucker: Use after treatment of retinal tears or retinal detachment. Arch Ophthalmol 106:758-760, 1988.
64. Cryotherapy for Retinopathy of Prematurity Cooperative Group: Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 106:471-479, 1988.
65. Kuwashima L, Graeber J and Glaser BM: Stimulation of endothelial cell prostacyclin release by retina-derived factors. Invest Ophthalmol Vis Sci 29:1213-1220, 1988.
66. de Bustros S, Thompson JT, Michels RG, Rice TA, and Glaser BM: Vitrectomy for idiopathic epiretinal membranes causing macular pucker. Br J Ophthalmol 72:692-695,

- 1988.
67. Del Priore LV, Glaser BM, Quigley HA, and Green WR: Response of pig retinal pigment epithelium to laser photocoagulation in organ culture. Arch Ophthalmol 107:119-122, 1989.
 68. Moisseiev J and Glaser BM: New and previously unidentified retinal breaks in eyes with recurrent retinal detachment with proliferative vitreoretinopathy. Arch Ophthalmol 107:1152-1154, 1989.
 69. Connor TB Jr, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, de Bustros S, Enger C, Kato H, Lansing, M, Hayashi H, and Glaser BM: Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 83:1661-1666, 1989.
 70. Smiddy WE, Glaser BM, Green WR, Connor TB Jr, Roberts AB, Lucas R, and Sporn MB: Transforming growth factor beta: A biologic chorioretinal glue. Arch Ophthalmol 107:577-580, 1989.
 71. Jerdan JA, Pepose JS, Michels RG, Hayashi H, de Bustros S, Sebag M, and Glaser BM: Proliferative vitreoretinopathy membranes: An immunohistochemical study. Ophthalmology 96:801-810, 1989.
 72. Joondeph BC, Flynn HW Jr., Blankenship GW, Glaser BM, and Stern WH: The surgical management of giant retinal tears with the cannulated extrusion needle. Am J Ophthalmol 108:548-553, 1989.
 73. Del Priore LV, Michels RG, Nunez MA, Smiddy W, Glaser BM, and de Bustros S: Intraocular pressure measurement after pars plana vitrectomy. Ophthalmology 96:1353-1356, 1989.
 74. Smiddy WE, Loupe D, Michels RG, Enger C, Glaser BM, de Bustros S: Extraocular muscle imbalance after scleral buckling surgery. Ophthalmology 96:1485-1489, 1989.
 75. Smiddy WE, Loupe DN, Michels RG, Enger C, Glaser BM, de Bustros S: Refractive changes after scleral buckling surgery. Arch Ophthalmol 107:1469-1471, 1989.
 76. MacCumber MW, Ross CA, Glaser BM, Snyder SH: Endothelin: Visualization of mRNAs by in situ hybridization provides evidence for local action. Proc Natl Acad Sci USA 86:7285-7289, 1989.
 77. Soubrane G, Jerdan J, Karpouzas I, Fayein NA, Glaser B, Coscas G, Courtois Y, Jeanny JC: Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest Ophthalmol Vis Science 31:323-333, 1990.
 78. de Bustros S, Michels RG, Glaser BM: Evolving concepts in the management of posterior segment penetrating ocular injuries. Retina 10 (Suppl 1):S72-S75, 1990.

79. Smiddy WE, Glaser BM, Michels RG, Vitale S: Miosis during vitreoretinal surgery. Retina 10:42-46, 1990.
80. Moisseiev J, Jerdan JA, Dyer K, Maglione A, Glaser BM: Retinal pigment epithelium cells can influence endothelial cell plasminogen activators. Invest Ophthalmol Vis Science 31:1070-1078, 1990.
81. Carter JB, Michels RG, Glaser BM, de Bustros S: Iatrogenic retinal breaks complicating pars plana vitrectomy. Ophthalmology 97:848-853, 1990.
82. Graeber JE, Glaser BM, Setty BNY, Jerdan JA, Walenga RW, and Stuart MJ: 15-Hydroxyeicosatetraenoic acid stimulates migration of human retinal microvessel endothelium in vitro and neovascularization in vivo. Prostaglandins 39:665-673, 1990.
83. Smiddy WE, Glaser BM, Michels RG, and de Bustros S: Scleral buckle revision to treat recurrent rhegmatogenous retinal detachment. Ophthalmic Surg 21:716-720, 1990.
84. Glaser BM: Extracellular modulating factors and the control of intraocular neovascularization: An overview. Jnl Diabetic Complications 4:108-112, 1990.
85. Michels RG and Glaser BM: Surgical treatment of postoperative dilated, nonreactive pupil in eyes after combined pars plana lensectomy and vitrectomy. Retina 10:205-208, 1990.
86. Cherfan GM, Michels RG, de Bustros S, Enger C, and Glaser BM: Nuclear sclerotic cataract after vitrectomy for idiopathic epiretinal membranes causing macular pucker. Am J Ophthalmol 111:434-438, 1991.
87. Glaser BM, Carter JB, Kuppermann BD, and Michels RG: Perfluoro-octane in the treatment of giant retinal tears with proliferative vitreoretinopathy. Ophthalmology 98:1613-1621, 1991.
88. Jerdan JA, Michels RG, and Glaser BM: Extracellular matrix of newly forming vessels — An immunohistochemical study. Microvascular Research 42:255-265, 1991.
89. Glaser BM, Michels RG, Kuppermann BD, Sjaarda RN, and Pena RA. Transforming growth factor- β_2 for the treatment of full-thickness macular holes. A prospective randomized study. Ophthalmology 99:1162-1173, 1992.
90. Glaser BM, Use of TGF-beta in treatment of macular holes. Vitreoretinal Surgery and Technology 4(6):8, 1992.
91. Glaser BM, Vidaurri-Leal J, Michels RG, and Campochiaro PA: Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology 100(4):466-470, 1993.

92. Lansing MB, Glaser BM, Liss H, Hanham A, Thompson JT, Sjaarda RN, and Gordon AJ: The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology 100(6):868-871, 1993.
93. Sjaarda RN, Frank DA, Glaser BM, Thompson JT, and Murphy RP: Assessment of vision in idiopathic macular holes with macular microperimetry using the scanning laser ophthalmoscope. Ophthalmology 100(10):1513-1518, 1993.
94. Sjaarda RN, Frank DA, Glaser BM, Thompson JT, and Murphy RP: Resolution of the absolute scotoma and improvement of relative scotomata following successful macular hole surgery. Results of macular microperimetry using the scanning laser ophthalmoscope. Am J Ophthalmol 116(2):129-139, 1993.
95. Ie D, Glaser BM, Thompson JT, Sjaarda RN, and Gordon LW: Retreatment of full-thickness macular holes persisting after prior vitrectomy. A pilot study. Ophthalmology 100(12):1787-1793, 1993.
96. Smiddy WE, Glaser BM, Thompson JT, Sjaarda RN, Flynn HW, Jr, Hanham A, and Murphy RP: Transforming growth factor β 2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes. Preliminary anatomic results of a multicenter prospective randomized study. Retina 13(4):296-301, 1993.
97. Alliegro MA, Dyer KD, Cragoe EJ, Jr, Glaser BM, and Alliegro MC: An HPLC method for quantitating plasma levels of amiloride and its analogues. J Chromatogr 582(1-2):217-23, 1993.
98. Ie D, Glaser BM, Sjaarda RN, Thompson JT, and Steinberg LE: The use of perfluorooctane in the management of giant retinal tears without proliferative vitreoretinopathy. Retina 14(4):323-8, 1994.
99. Ie D, Glaser BM, Ramsey CL, Gordon LW, Jerden JA, and Pena RA: Transforming growth factor-beta 2 levels increase following retinal laser photocoagulation. Curr Eye Res 13(10):743-6, 1994.
100. Pena RA, Jerden JA, and Glaser BM: Effects of TGF- β and TGF- β neutralizing antibodies on fibroblast-induced collagen gel contraction: implications for proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 35(6):2804-8, 1994
101. Thompson JT; Glaser BM; Sjaarda RN; Murphy RP; Hanham A: Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta2. Ophthalmology 101(7):1195-200, 1994.
102. Thompson JT; Hiner CJ; Glaser BM; Gordon AJ; Murphy RP; Sjaarda RN: Fluorescein angiographic characteristics of macular holes before and after vitrectomy with transforming growth factor beta-2. Am J Ophthalmol 117 (3): 291-301, 1994.

103. Ie D; Glaser BM; Murphy RP; Gordon LW; Sjaarda RN; Thompson JT: Indocyanine green angiography in multiple evanescent white-dot syndrome. Am J Ophthalmol 117 (1): 7-12, 1994.
104. Thompson JT, Glaser BM, Sjaarda RN, Murphy RP, Hanham A: Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2. Ophthalmology 101 (7):1195-2000, July 1994.
105. Thompson JT, Hiner CJ, Glaser BM, Gordon AJ, Murphy RP, Sjaarda RN: Fluorescein angiographic characteristics of macular holes before and after vitrectomy with transforming growth factor beta-2. Am J Ophthalmol 117(3):291-301, March 1994.
106. Ie D, Glaser BM, Murphy RP, Gordon LW, Sjaarda RN, Thompson JT: Indocyanine green angiography in multiple evanescent white-dot syndrome. Am J Ophthalmol 117 (1):7-12, January 1994.
107. Ie D, Glaser, BM, Sjaarda RN, Thompson JT, Steinberg LE, Gordon LW: The use of perfluoro-octane in the management of giant retinal tears without proliferative vitreoretinopathy. Retina 14(4):323-8, 1994.
108. Thompson, JT; Glaser BM; Sjaarda RN; Murphy RP: Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. Am J Ophthalmol 119(1):48-54, 1995.
109. Klein BR, Hiner CJ, Glaser BM, Murphy RP, Sjaarda RN, and Thompson JT: Fundus photographic and fluorescein angiographic characteristics of pseudoholes of the macula in eyes with epiretinal membranes. Ophthalmology 102(5):768-74, 1995.
110. Rubin JS, Glaser BM, Thompson JT, Sjaarda RN, Pappas SS, Murphy RP: Vitrectomy, fluid-gas exchange and transforming growth factor-beta-2 for the treatment of traumatic macular holes. Ophthalmology 102 (12):1840-45, December 1995.
111. Gordon LW, Glaser BM, Ie D, Thompson JT, Sjaarda RN: Full-thickness macular hole formation in eyes with a pre-existing complete posterior vitreous detachment. Ophthalmology 102 (11):1702-5, November 1995.
112. Sjaarda RN, Glaser BM, Thompson JT, Murphy RP, Hanham A: Distribution of iatrogenic retinal breaks in macular hole surgery. Ophthalmology 102 (9):1387-92, September 1995.
113. Klein BR, Hiner CJ, Glaser BM, Murphy RP, Sjaarda RN, Thompson JT: Fundus photographic and fluorescein angiographic characteristics of pseudoholes of the macula in eyes with epiretinal membranes. Ophthalmology 102 (5):768-74, May 1995.
114. Rubin JS, Thompson JT, Sjaarda RN, Pappas SS Jr, Glaser BM: Efficacy of fluid-air exchange during pars plana vitrectomy. Retina 15 (4): 291-4, 1995.
115. Thompson JT, Glaser BM, Sjaarda RN, Murphy RP: Progression of nuclear sclerosis and

long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. Am J Ophthalmol 119 (1): 48-54, January 1995.

116. Rosa RH Jr, Glaser BM, de la Cruz Z, Green WR: Clinicopathologic correlation of an untreated macular hole and a macular hole treated by vitrectomy, transforming growth factor-beta 2, and gas tamponade. Am J Ophthalmol 122 (6): 853-63, December 1996.
117. Thompson JT, Sjaarda RN, Glaser BM, Murphy RP: Increased intraocular pressure after macular hole surgery. Am J Ophthalmol 121 (6): 615-22, June 1996.
118. Smiddy WE, Sjaarda RN, Glaser BM, Flynn HW Jr, Thompson JT, Hanham A, Murphy RP: Reoperation after failed macular hole surgery. Retina 16 (1):13-8, 1996.
119. Thompson JR, Smiddy WE, Glaser BM, Sjaarda RN, Flynn HW Jr: Intraocular tamponade duration and success of macular hole surgery. Retina 16 (5): 373-82, 1996.
120. Lin SB, Glaser BM, Gould DM, Baudo TA, Lakhanpal RR, Murphy RP: Scleral Outfolding for Macular Translocation. Am J Ophthalmol 130:74-79, 2000.
121. Johnson TM, Glaser BM: Micropulse Laser Treatment of Retinalchoroidal Anastomoses in Age-related Macular Degeneration. Graefe's Arch Clin Exp Ophthalmol 243:570-575, 2005.
122. Johnson TM, Glaser BM: Intraocular Rake for Removal of Epiretinal Membranes. Am J Ophthalmol. Am J Ophthalmol 141:381-383, 2006.
123. Johnson TM, Glaser BM: Focal Laser Ablation of Retinal Angiomatous Proliferation. Retina 26:765-772, 2006.
124. Glaser BM, Grodin, MH, Acree, JL: A New Era of Ophthalmic Surgical Training: A high Fidelity Surgical Simulator and Performance Driven Training. Highlights of Ophthalmology 34 (5)10-12, 2006.
125. Grodin MH, Johnson TM, Acree, JL, Glaser, BM: Ophthalmic Surgical Training: A Curriculum to Enhance Surgical Simulation. Retina 28:1509-1514, 2008.
126. Davuluri G, Espina V, Petricoin E, Ross M, Deng J, Liotta, L, Glaser, B: Activated VEGF Receptor Shed Into the Vitreous in Eyes with Wet AMD: A New Class of Biomarkers in the Vitreous with Potential for Predicting the Treatment Timing and Monitoring Response. Arch. Ophthalmol. Submitted.
127. Glaser B: Surgical Simulation: Why Now?. (Editorial) Retina. In Press.

Book Chapters

1. Glaser BM and Patz A: Ocular Neovascularization: Current Concepts: In Little H, Patz A, Jack RL, Forsham PH, and Aiello L (Eds.): Diabetic Retinopathy. Thieme-Stratton,

New York, pp. 367-390, 1983.

2. Glaser BM: Angiogenesis Factors in Ocular Disease. In Abe H and Hoshi M (Eds.): Diabetic Microangiopathy. Japan Medical Research Foundation Publication No. 20, University of Tokyo Press, Japan, pp. 25-38, 1983.
3. Glaser BM: Clinical Studies of Diabetic Retinopathy in the United States. In Abe H and Hoshi M (Eds.): Diabetic Microangiopathy. Japan Medical Research Foundation Publication No. 20, University of Tokyo Press, Japan, pp. 297-305, 1983.
4. Glaser BM, Kalebic T, Garbisa S, Connor TB, and Liotta LA: Degradation of Basement Membrane Components by Vascular Endothelial Cells: Role in Neovascularization. In Wolpert L (Ed.): Ciba Foundation Symposium No. 100: Development of the Vascular System, pp 150-162, 1983.
5. Glaser BM: Cell Biology and Biochemistry of Endothelial Cells and the Phenomenon of Intraocular Neovascularization. In Adler R and Farber D (Eds.): The Retina: A Model for Cell Biology Studies (Part II). Academic Press, Orlando, FL, pp. 215—243, 1987.
6. Glaser BM and Davis JL: Retinal Pigment Epithelial Cells Inhibit Vascular Endothelial Cells Invasion. In BenEzra D, Ryan SJ, Glaser BM, and Murphy RP (Eds.): Ocular Circulation and Neovascularization. Martinus Nijhoff/Dr. W. Junk Publishers, Dordrecht, pp. 525-528, 1987.
7. Glaser BM, Campochiaro PA, Davis JL Jr, and Jerdan JA: Retinal Pigment Epithelial Cells Release Inhibitors of Neovascularization. In BenEzra D, Ryan SJ, Glaser BM, and Murphy RP (Eds.): Ocular Circulation and Neovascularization. Martinus Nijhoff/Dr. W. Junk Publishers, Dordrecht, pp. 535-543, 1987.
8. Glaser BM, Kuwashima L, Sato M, and Adler R: The Formation and Maintenance of New Blood Vessels. In BenEzra D, Ryan SJ, Glaser BM, and Murphy RP (Eds.): Ocular Circulation and Neovascularization. Martinus Nijhoff/Dr. W. Junk Publishers, Dordrecht, pp. 77-83, 1987.
9. Glaser BM: Future Trends and Concepts. In BenEzra D, Ryan SJ, Glaser BM, and Murphy RP (Eds.): Ocular Circulation and Neovascularization. Martinus Nijhoff/Dr. W. Junk Publishers, Dordrecht, pp. 565-567, 1987.
10. Glaser B: Retinal Pigment Epithelial Cells Release Inhibitors of Neovascularization. In Rifkin DB and Klagsbrun M (Eds.): Current Communications in Molecular Biology: Angiogenesis Mechanisms and Pathobiology. Cold Spring Harbor Publications, Cold Spring Harbor, NY, pp. 114-118, 1987.
11. Glaser BM, Campochiaro PA, Davis JL Jr, and Sato M: Retinal Pigment Epithelial Cells Release an Inhibitor of Neovascularization. In Flynn JT and Phelps DL (Eds.): Retinopathy of Prematurity: Problem and Challenge. Birth Defects: Original Article Series, Vol. 24:1. Alan R. Liss, Inc., New York, pp. 121-127, 1988.

12. Glaser BM: Pathobiology of PVR. In Freeman HM and Tolentino FI (Eds.): Proliferative Vitreoretinopathy (PVR). Springer-Verlag, New York, 1988, pp. 12-21.
13. Glaser BM and Lemor M: Pathobiology of Proliferative Vitreoretinopathy. In (Ryan SJ, Editor-in-Chief): Retina. Vol. 3. Surgical Retina (Glaser BM and Michels RG, Eds.). C.V. Mosby Company, St. Louis, 1989, pp. 369-383.
14. Glaser BM: Surgery for Proliferative Vitreoretinopathy. In (Ryan SJ, Editor-in-Chief): Retina. Vol. 3. Surgical Retina (Glaser BM and Michels RG, Eds.). C.V. Mosby Company, St. Louis, 1989, pp. 385-400.
15. Glaser BM: Treatment of Giant Tears Combined With Proliferative Vitreoretinopathy. In (Ryan SJ, Editor-in-Chief): Retina. Vol. 3. Surgical Retina (Glaser BM and Michels RG, Eds.). C.V. Mosby Company, St. Louis, 1989, pp. 449-454.
16. Glaser BM: Extracellular Modulating Factors and The Control of Intraocular Neovascularization: An Overview. In (Ryan SJ, Editor-in-Chief): Retina. Vol. 3. Surgical Retina (Glaser BM and Michels RG, Eds.). C.V. Mosby Company, St. Louis, 1989, pp. 503-514.
17. Glaser B: Does Pneumatic Retinopexy Stimulate Vitreoretinopathy? Part II. In Tornambe PE and Grizzard WS (Eds.): Pneumatic Retinopexy: A Clinical Symposium. Greenwood Publishing, Des Plaines, IL, 1989, pp. 113-116.
18. Glaser B: Clinical Experience: Baltimore, Maryland. In Tornambe PE and Grizzard WS (Eds.): Pneumatic Retinopexy: A Clinical Symposium. Greenwood Publishing, Des Plaines, IL., 1989, pp. 170-171.
19. Glaser BM, Connor Jr TB, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, de Bustros S, Enger C: Correlation of Fibrosis and Transforming Growth Factor-beta Type 2 Levels in the Eye. In Heimann K and Wiedemann P (Eds.): Proliferative Vitreoretinopathy. Kaden Verlag, Heidelberg, 1989, pp. 120-127.
20. Glaser, BM: Angiogenèse. In Coscas G (Ed.): Dégénérescences Maculaires Acquisées Liées à l'Âge et Néovaisseaux Sous-Rétiniens. Masson, Paris, 1991, pp. 63-69.
21. Glaser BM, Carter JB, Kuppermann BD, and Michels RG: Perfluorooctane in the Treatment of Giant Retinal Tears With Proliferative Vitreoretinopathy. In Olk RJ (Ed.): New Approaches to Vitreoretinal Surgery. International Ophthalmology Clinics, Vol. 32, No. 2, Spring 1992, Little, Brown and Company, Boston, 1992, pp. 1-14.
23. Carter JB, Glaser BM, Michels RG, and Allarakhia L: An apparatus for viscodissection of epiretinal fibrovascular tissue, In Stirpe, M (Ed.): Fondazione G.B. Bietti per l'Oftalmologia: 3rd Int Symp on Vitreoretinal Surgery, Rome, Italy, September 12 to 16, 1991, Ophthalmic Communications Society, New York, 1992, 79-81.
24. Glaser BM and Michels RG: Surgical techniques using perfluoro-n-octane in the treatment of selected giant retinal tears with an inverted posterior retinal flap, In Stirpe,

M (Ed.): Fondazione G.B. Bietti per l'Oftalmologia: 3rd Int Symp on Vitreoretinal Surgery, Rome, Italy, September 12 to 16, 1991, Ophthalmic Communications Society, New York, 1992, 64-71.

25. Glaser BM and Smiddy WE: Transforming Growth Factor Beta — A Biologic Chorioretinal Glue: Its Role In Retinal Wound Healing. In Gearing AJH, Rossio JL, Oppenheim JJ (Eds.): Clinical Applications of Cytokines: Role In Pathogenesis, Diagnosis, and Therapy, Oxford University Press, New York, in press 1992.
26. Glaser BM, Michels RG, Kuppermann BD, Sjaarda RN, and Pena RA: Transforming Growth Factor- β_2 For The Treatment of Full-Thickness Macular Holes: A Prospective Randomized Study. In Lewis H and Ryan SJ (Eds.): Medical and Surgical Retina: Advances, Controversies, and Management. Mosby-Year Book, St. Louis, 1994, 241-251.
27. Glaser BM and Lemor M: Pathobiology of Proliferative Vitreoretinopathy. In (Ryan SJ, Editor-in-Chief): Retina. Vol. 3. Surgical Retina (Glaser BM, Ed.), 2nd ed., Mosby-Yearbook, St. Louis, 1994, 2249.
28. Glaser BM: Surgery for Proliferative Vitreoretinopathy. In (Ryan SJ, Editor-in-Chief): Retina. Vol. 3. Surgical Retina (Glaser BM, Ed.), 2nd ed., Mosby-Yearbook, St. Louis, 1994, 2265.
29. Glaser BM: Treatment of Giant Tears Combined with Proliferative Vitreoretinopathy. In (Ryan SJ, Editor-in-Chief): Retina. Vol. 3. Surgical Retina (Glaser BM, Ed.), 2nd ed., Mosby-Yearbook, St. Louis, 1994, 2329.
30. Glaser BM: Management of Idiopathic Macular Holes. In (Ryan SJ, Editor-in-Chief): Retina. Vol. 3. Surgical Retina (Glaser BM, Ed.), 2nd ed., Mosby-Yearbook, St. Louis, 1994, 2379.
31. Glaser BM: Extracellular Modulating Factors and The Control of Intraocular Neovascularization: An Overview. In (Ryan SJ, Editor-in-Chief): Retina. Vol. 3. Surgical Retina (Glaser BM, Ed.), 2nd ed., Mosby-Yearbook, St. Louis, 1994, 2395.
32. Glaser BM: TGF Beta for the Treatment of Full-Thickness Macular Hole. In Bovino J, Ed., Macular Surgery, Applton & Lange, Norwalk, CT, 1994.
33. Glaser BM and Johnson TM: Choroidal Feeder Vessel Photocoagulation Therapy. In Alfaro III DV, Liggett PE, Mieler WF, Quiroz-Mercado H, Jager RD and Tano Y (Eds) Age-Related Macular Degeneration. A Comprehensive Textbook, Lippincott Williams and Wilkins, Philadelphia, PA, 2005, pp 231-241.

Clinical Trials

1. FVF4168g – A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled

Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus.

2. WIRB Protocol #20051556 – An Observational Case Series of Patients Who Underwent Surgery for Full Thickness Macular Holes and Assessed Pre- and Post-Operatively With the Micro Perimeter (MP1)
3. VGFT-OD-0508 – A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration
4. FVF3689g – A Phase IIIb, Multicenter Study to Evaluate the Safety and Tolerability of RANibizmab in Naïve and Previously Treated Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
5. FVF3426g – An Open Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Who Have Completed the Treatment Phase of a Genentech-Sponsored Ranibizumab Study
6. WIRB Protocol #20051228 – Phase I Study of Intravitreal Lucentis For The Treatment of Stage 1 and 2 Retinal Angiomatous Proliferations
7. WIRB Protocol #20060001 – The Vitreous Proteome
8. WIRB Protocol #20052536 – Comparison of Intravitreal Versus Anterior Sub-Tenon’s Injection of Triamcinolone Acetonide for Refractory Diabetic Macular Edema, A Randomized Clinical Trial
9. FVF2428g – A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination with Verteporfin (Visudyne™) Photodynamic Therapy in Subjects With Neovascular Age-Related Macular Degeneration
10. FVF2598g – A Phase III, Multicenter, Randomized, Double-Masked, Sham-Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration
11. CLEAR-IT 1 – A Phase I, Dose-Escalation, Safety, Tolerability, and Bioactivity Study of Intravitreal VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration
12. EOP1004F – A Phase II/III Randomized, Double Masked, Controlled, Dose-Ranging, Multi-Center Comparative Trial, in Parallel Groups, To Establish the Safety and Efficacy of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks For 54 Weeks, in Patients With Exudative Age-Related Macular Degeneration (AMD)
13. AG3340-801 – A Phase II, Randomized, Double-Masked, Placebo-Controlled Study of the Matrix Metalloproteinase Inhibitor AG3340 in Patients With Subfoveal Choroidal

Neovascularization Associated with Age-Related Macular Degeneration

14. B7A-MC-MBBK – Protein Kinase C Inhibitor β - Diabetic Macular Edema Study
15. B7A-MC-MBBM – Protein Kinase C Inhibitor β - Diabetic Retinopathy Study
16. AMD-02-99 – A Multicenter, Prospective, Randomized, Double-Masked Study Comparing the Safety and Efficacy of Membrane Differential Filtration to a Placebo Treatment in Patients with Non-Exudative Age-Related Macular Degeneration
17. PDTP-920101-OP004 – Phase I/II SnET2 Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration
18. PDTP-920101-OP002 – Phase I/II SnET2 Treatment of Subfoveal Choroidal Neovascularization
19. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group study.

Books

1. BenEzra D, Ryan SJ, Glaser BM, and Murphy RP (Eds.): Ocular Circulation and Neovascularization. Martinus Nijhoff/Dr. W. Junk Publishers, Dordrecht, 1987.
2. Glaser BM (ed): Ryan SJ (Editor-in-Chief), Retina, Vol. 3, Surgical Retina, C.V. Mosby, St. Louis, 1989.
3. Glaser BM: Atlas of Retinal Surgery. J. B. Lippincott Company, Philadelphia, PA. in preparation, 1988.
4. Glaser BM (Ed.): Ryan SJ (Editor-in-Chief), Retina, Vol. 3, Surgical Retina, 2nd ed., Mosby-Yearbook, St. Louis, 1994.

Abstracts

1. Aguayo JB, Glaser BM, Cheng H-M, Gonzales RG, and Barnett P: Detection of intraocular melanoma by NMR proton imaging. ARVO Annual Spring Meeting, Sarasota, 1984. Invest Ophthalmol Vis Sci (Suppl) 25:3, 1984. p. 49.
2. Sato S, Adler R, and Glaser BM: Reaggregated endothelial cells form capillary-like structures. ARVO Annual Spring Meeting, Sarasota, 1984. Invest Ophthalmol Vis Sci (Suppl) 25:3, 1984, p. 66.
3. Jerdan JA and Glaser BM: The extracellular matrix of the human retinal vasculature. ARVO Annual Spring Meeting, Sarasota, 1984. Invest Ophthalmol Vis Sci (Suppl) 25:3, 1984, p. 247.

4. Campochiaro PA, Jerdan JA, and Glaser BM: Human serum contains chemoattractants for human retinal pigment epithelial cells. ARVO Annual Spring Meeting, Sarasota, 1984. Invest Ophthalmol Vis Sci (Suppl) 25:3, 1984, p. 272.
5. Rowen S and Glaser B: Endothelial cells release a stimulator of astrocyte migration. ARVO Annual Spring Meeting, Sarasota, 1984. Invest Ophthalmol Vis Sci Suppl 25:3, 1984, p. 273.
6. Vidaurri-Leal JS and Glaser BM: The effect of fibrin on retinal pigment epithelial cell morphology. ARVO Annual Spring Meeting, Sarasota, 1984. Invest Ophthalmol Vis Sci (Suppl) 25:3, 1984, p. 273.
7. Thompson JT and Glaser BM: The effect of extracapsular lensectomy and posterior capsulotomy on the movement of tracers from vitreous to aqueous. ARVO Annual Spring Meeting, Sarasota, 1984. Invest Ophthalmol Vis Sci (Suppl) 25:3, 1984, p. 308.
8. de Bustros S, Glaser BM, Johnson M, and de Juan E: Thrombin infusion for the control of intraocular bleeding during vitreous surgery. ARVO Annual Spring Meeting, Sarasota, 1984. Invest Ophthalmol Vis Sci (Suppl) 25:3, 1984, p. 309.
9. Davis JL Jr, Connor TB Jr, and Glaser BM: Purification of tissue plasminogen activator from vascular endothelial cells. ARVO Annual Spring Meeting, Sarasota, 1984. Invest Ophthalmol Vis Sci (Suppl) 25:3, 1984, p. 316.
10. Cassel GH, Jerdan JA, and Glaser BM: Partial isolation of a stimulator of plasminogen activator from retinal extract. ARVO Annual Spring Meeting, Sarasota, 1985. Invest Ophthalmol Vis Sci (Suppl) 26:3, 1985, p. 25.
11. Sadeghi J, Yeo JH, Campochiaro PA, and Glaser BM: Intravitreal fibronectin and platelet-derived growth factor: A new model for proliferative vitreoretinopathy. ARVO Annual Spring Meeting, Sarasota, 1985. Invest Ophthalmol Vis Sci (Suppl) 26:3, 1985, p. 25.
12. McDonnell PJ, Glaser BM, Rowen SL, and Sato M: Posterior capsule opacification: An in vitro model. ARVO Annual Spring Meeting, Sarasota, 1985. Invest Ophthalmol Vis Sci (Suppl) 26:3, 1985, p. 120.
13. Glaser BM, Campochiaro PA, and Sato M: How does PRP work? A novel approach to an unanswered question. ARVO Annual Spring Meeting, Sarasota, 1985. Invest Ophthalmol Vis Sci (Suppl) 26:3, 1985, p. 170.
14. Rowen SL and Glaser BM: Retinal pigment epithelial cells release a chemoattractant for astrocytes. ARVO Annual Spring Meeting, Sarasota, 1985. Invest Ophthalmol Vis Sci (Suppl) 26:3, 1985, p. 170.
15. Jerdan JA, Campochiaro PA, and Glaser BM: Vitreous aspirates from eyes with proliferative vitreoretinopathy stimulate RPE migration. ARVO Annual Spring Meeting,

- Sarasota, 1985. Invest Ophthalmol Vis Sci (Suppl) 26:3, 1985, p. 283.
16. Graeber JE and Glaser BM: Hyperoxia alters endothelial cell proliferation. ARVO Annual Spring Meeting, Sarasota, 1985. Invest Ophthalmol Vis Sci (Suppl) 26:3, 1985, p. 284.
 17. Sato M, Adler R, and Glaser BM: Histogenesis in aggregates of vascular endothelial cells co-cultivated with smooth muscle cells & fibroblasts. ARVO Annual Spring Meeting, Sarasota, 1985. Invest Ophthalmol Vis Sci (Suppl) 26:3, 1985, p. 329.
 18. Glaser BM, Davis JL Jr, and Campochiaro PA. Human RPE can inhibit proteases involved in neovascularization. ARVO Annual Spring Meeting, Sarasota, 1986. Invest Ophthalmol Vis Sci (Suppl) 27:3, 1986, p. 306.
 19. Golnik K and Glaser BM. Heparin induces a fibroblast-derived inhibitor of vascular endothelial cell proliferation. ARVO Annual Spring Meeting, Sarasota, 1986. Invest Ophthalmol Vis Sci (Suppl) 27:3, 1986, p. 306.
 20. Lemor M, Yeo JH, and Glaser BM. Oral colchicine inhibits experimental traction retinal detachment. ARVO Annual Spring Meeting, Sarasota, 1986. Invest Ophthalmol Vis Sci (Suppl) 27:3, 1986, p. 186.
 21. Avery RL and Glaser BM. Inhibition of retinal pigment epithelial cell attachment and migration by a synthetic peptide from the cell-binding domain of fibronectin. ARVO Annual Spring Meeting, Sarasota, 1986. Invest Ophthalmol Vis Sci (Suppl) 27:3, 1986, p. 187.
 22. Yeo JH and Glaser BM. Isoelectric focusing analysis of subretinal fluid from rhegmatogenous retinal detachments. ARVO Annual Spring Meeting, Sarasota, 1986. Invest Ophthalmol Vis Sci (Suppl) 27:3, 1986, p. 318.
 23. Thompson JT and Glaser BM. The role of the vitreous and lensectomy on the movement of myosin from vitreous to aqueous. ARVO Annual Spring Meeting, Sarasota, 1986. Invest Ophthalmol Vis Sci (Suppl) 27:3, 1986, p. 316.
 24. Jerdan JA, Kao L, and Glaser BM. The inner limiting membrane - A modified basement membrane? ARVO Annual Spring Meeting, Sarasota, 1986. Invest Ophthalmol Vis Sci (Suppl) 27:3, 1986, p. 230.
 25. McDonnell PJ, Krause W, and Glaser BM. In vitro inhibition of lens epithelial cell proliferation. ARVO Annual Spring Meeting, Sarasota, 1986. Invest Ophthalmol Vis Sci (Suppl) 27:3, 1986, p. 272.
 26. de Bustros S, Lemor M, Sato M, and Glaser B. Colchicine inhibits RPE and fibroblast migration. ARVO Annual Spring Meeting, Sarasota, 1986. Invest Ophthalmol Vis Sci (Suppl) 27:3, 1986, p. 305.
 27. Singh AK, Glaser BM, Lemor M, and Michels RG. Behavior of viable pigment epithelial

- cells released into the vitreous. ARVO Annual Spring Meeting, Sarasota, 1986. Invest Ophthalmol Vis Sci (Suppl) 27:3, 1986, p. 309.
28. Smith PW, Stark WJ, Maumenee AE, Auer C, Michels RG, and Glaser BM. Retinal detachment after posterior chamber IOL implantation. ARVO Annual Spring Meeting, Sarasota, 1986. Invest Ophthalmol Vis Sci (Suppl) 27:3, 1986, p. 45.
 29. Glaser B, Davis J, Hyer K, Jerdan J, Hewitt T, and Krause W. Purification of a diffusible RPE-derived protease inhibitor and localization within Bruch's membrane: possible role in the control of intraocular neovascularization. ARVO Annual Spring Meeting, Sarasota, 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 49.
 30. Avery R, Biscoe B, and Glaser B. Detachment of retinal pigment epithelial cells growing within collagen gels by a synthetic peptide from the cell-binding domain of fibronectin: possible adjunct to vitreous surgery. ARVO Annual Spring Meeting, Sarasota 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 290.
 31. Isernhagen R, Glaser B, Lemor M, Guedeney X, and Scherrmann J-M. Colchicine levels in human blood & vitreous fluid following oral administration. ARVO Annual Spring Meeting, Sarasota, 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 116.
 32. Kuwashima L and Glaser B. Procoagulant activity of retinal vascular endothelial cells is induced by RPE cells: role in regression of neovascularization. ARVO Annual Spring Meeting, Sarasota, 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 204.
 33. Bartov E, Jerdan J, Glaser B. Astrocytes decrease the permeability of human retinal microvessel endothelial monolayers in culture. ARVO Annual Spring Meeting, Sarasota, 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 203.
 34. Graeber JE, Glaser BM, Jerdan J, and Stuart MJ. 15-hydroxyeicosatetraenoic acid (15-HETE) stimulates migration of human retinal microvessel endothelium in vitro and neovascularization in vivo. ARVO Annual Spring Meeting, Sarasota, 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 203.
 35. Hayashi H, Jerdan J, Michels R, and Glaser B. Plasminogen activator activity of preretinal membranes from eyes with proliferative diabetic retinopathy (PDR). ARVO Annual Spring Meeting, Sarasota, 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 204.
 36. Davis J, Connor T, Krause W, Hyer K, and Glaser B. Ocular modulators of RPE protease inhibitors: role in control of neovascularization (NV). ARVO Annual Spring Meeting, Sarasota, 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 204.
 37. Connor T and Glaser B. RPE cells can simultaneously release inhibitors and stimulators of endothelial cell proliferation. ARVO Annual Spring Meeting, Sarasota, 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 203.
 38. deBustros S, Thompson JT, Enger C, Michels RG, Rice TA, and Glaser, BM. Nuclear

- sclerosis after vitrectomy for idiopathic epiretinal membranes. ARVO Annual Spring Meeting, Sarasota, 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 322.
39. Jerdan J, Pepose J, Maglione A, Michels R, and Glaser B. PVR membranes — An immunohistochemical study. ARVO Annual Spring Meeting, Sarasota, 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 115.
 40. Jerdan J, Glaser B, and Schiffman E. Immunohistochemical examination of capillary sprout extracellular matrix. J Cell Biology 105:4, Part 2, October 1987, p. 328a.
 41. Connor T, Hayashi H, Krause W, Davis J, and Glaser BM. Transforming growth factor-beta (TGF-b) inhibits plasminogen activator activity of vascular endothelial cells. J Cell Biology 105:4, Part 2, October 1987, p. 274a.
 42. Selden SC, Glaser BM, Roberts AB, Sporn MB, and Tucker RW. Transforming growth factor-beta (TGF-b) may inhibit endothelial cell proliferation in response to basic fibroblast growth factor (b-FGF) via a calcium-dependent second messenger pathway. J Cell Biology 105:4, Part 2, October 1987, p. 23a.
 43. Selden SC, Glaser BM, and Tucker RW. Heparin inhibition of smooth muscle cell (SMC) proliferation in vitro may function through a calcium-dependent second messenger pathway. J Cell Biology 105:4, Part 2, October 1987, p. 103a.
 44. Lemor M, Hyer K, Davis J, Connor T, and Glaser B. Sub-retinal fluid from experimental retinal detachments stimulates RPE cell and astrocyte proliferation. ARVO Annual Spring Meeting, Sarasota, 1987. Invest Ophthalmol Vis Sci (Suppl) 28:3, 1987, p. 206.
 45. Hayashi H, Jerdan J, Kato H, and Glaser B. Localization of transforming growth factor-beta (TGF-Beta) within the retina and choroid following argon laser photocoagulation (ALP). ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 221.
 46. Maglione A, Jerdan JA, and Glaser BM. Vascular endothelial cells in aggregate culture make intercellular junctions typical of established vessels. ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 200.
 47. Del Priore LV, Glaser BM, Quigley HA, and Green WR. Organ culture of retinal pigment epithelium (RPE) and its response to photocoagulation. ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 291.
 48. Kato H, Lansing M, Hayashi H, and Glaser B. Experimental traction retinal detachment (TRD) after intravitreal injection of combinations of platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-b) and fibronectin (FN). ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 307.
 49. Connor T, Roberts A, Sporn M, Davis J, and Glaser B. RPE cells synthesize and release transforming growth factor-beta, a modulator of endothelial cell growth and wound healing. ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci

(Suppl) 29:3, 1988, p. 307.

50. Lansing MB and Glaser BM. Inhibition of corneal neovascularization (NV) by a partially purified preparation of human retinal pigment epithelial (RPE) cell conditioned medium. ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3,1988, p. 246.
51. Smiddy WE, Connor TB Jr, Green WR, Roberts AB, Sporn MB, and Glaser BM. Transforming growth factor beta - A biologic retinal glue. ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 221.
52. MacCumber MW, Connor TB, Hayashi H, Krause WG, and Glaser BM. Transforming growth factor beta (TGF-b) modulates vascular endothelial cell protease activity: role in new blood vessel invasion. ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 246.
53. Selden SC, Glaser BM, Roberts AB, Sporn MB, and Tucker RW. Inhibition of basic-fibroblast growth factor (FGF) induced vascular proliferation by transforming growth factor-beta (TGF-B) is associated with inhibition of cytoplasmic calcium elevation. ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 307.
54. Kuwashima L and Glaser B. Transforming growth factor-beta from RPE induces vascular endothelial cell thrombogenicity: potential role in the regression of neovascularization. ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 246.
55. Avery R and Glaser B. A synthetic laminin analog inhibits RPE cell migration. ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 307.
56. Glaser BM, Hayashi H, and Krause WG. A protease inhibitor accumulates within the vitreous following pan retinal photo-coagulation (PRP) in primates: possible mechanism for the effect of PRP on retinal neovascularization. ARVO, Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 180.
57. Jerdan JA, Kristensen P, Maglione A, and Glaser BM. New blood vessel formation is associated with urokinase-type plasminogen activator (u-PA). ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 109.
58. Soubrane G, Courtois Y, Jerdan J, Glaser B, and Jeanny J CL. Iodinated bFGF specific fixation to prostaglandins induced new-vessels in rabbit cornea. ARVO Annual Spring Meeting, Sarasota, 1988. Invest Ophthalmol Vis Sci (Suppl) 29:3, 1988, p. 287.
59. Adamsons I, Jerdan JA, Lansing M, Martin GR, and Glaser BM: Inhibition of neovascularization by a peptide analog of the cell-binding domain of laminin. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 391.

60. Avery R, Giavedoni L, and Glaser B: Transforming growth factor-beta stimulates RPE cell mediated contraction of collagen gels. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 393.
61. Giavedoni LR, Selden SC, Jerdan JA, and Glaser BM: A model for studying RPE cell migration and proliferation on basement membrane. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 413.
62. Hayashi H, Kato H, Oshima K, Jerdan J, Baird A, and Glaser BM: Accumulation of basic fibroblast growth factor (b-FGF) in photocoagulation scars. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 239.
63. Kato H, Hayashi H, Oshima K, Jerdan J, Baird A, and Glaser BM: Localization of basic-fibroblast growth factor in the developing rat eye. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 464.
64. Lansing M, Jerdan J, Dugan J, Maglione A, and Glaser B: The bifunctional role of transforming growth factors beta-1 (TGF-beta 1) and beta-2 (TGF-beta 2) in neovascularization in the mature animal. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 392.
65. MacCumber M, Ross C, Snyder S, and Glaser B: Endothelin, a vasoconstrictive peptide, is synthesized by human retinal microvessel endothelial cells in culture. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 465.
66. Maglione A, Jerdan JA, and Glaser BM: Formation of tube-like structures by endothelial cells on corneal stroma. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 464.
67. Moisseiev J, Jerdan J, Dyer K, and Glaser B: Endothelial plasminogen activator (PA) release can be influenced by RPE cells & fibroblasts. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 393.
68. Selden SC and Glaser BM: Human retinal microvascular endothelial cell (HME) growth inhibition by TGF-b is modulated by cell population density in vitro. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 395.
69. Glaser BM, Adamsons I, Lansing M, Jerdan J, and Davis J: A urokinase inhibitor derived from human RPE cells inhibits neovascularization in vivo. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 395.
70. Dugan JD Jr, Lansing M, Jerdan JA, Selden CS, and Glaser BM: Transforming growth factor beta (TGFb) inhibits embryonic neovascularization in vivo. ARVO Annual Spring Meeting, Sarasota, 1989. Invest Ophthalmol Vis Sci (Suppl) 30:3, 1989, p. 466.
71. Dugan JD Jr, Jerdan J, Lansing M, and Glaser BM: Retinopathy of prematurity: An immunohistochemical study of retrolental membranes. ARVO Annual Spring Meeting,

- Sarasota, 1990. Invest Ophthalmol Vis Sci 31:4, 1990, p. 132.
72. MacCumber MW, Jampel HD, Glaser BM, Quigley HA, and Snyder SH: Ocular response to endothelin, a potent vasoconstrictive peptide. ARVO Annual Spring Meeting, Sarasota, 1990. Invest Ophthalmol Vis Sci 31:4, 1990, p.381.
 73. Lansing MB, Dugan J, and Glaser BM: The triple pocket corneal assay — A new approach to angiogenesis. ARVO Annual Spring Meeting, Sarasota, 1990. Invest Ophthalmol Vis Sci 31:4, 1990, p. 486.
 74. Glaser BM and Michels, RG: Induction of a "retinal patch" by transforming growth factor-beta in the treatment of full thickness macular holes. ARVO Annual Spring Meeting, Sarasota, 1991, Invest Ophthalmol Vis Sci 32:4, 1991, p. 713.
 75. Alliegro MA, Dyer KD, Glaser BM, and Alliegro MC: An HPLC method for quantiating blood amiloride levels. ARVO Annual Spring Meeting, Sarasota, 1991, Invest Ophthalmol Vis Sci 32:4, 1991, p. 771.
 76. Dyer KD, Varner HH, Cragoe EJ, and Glaser BM: N- (diaminomethylene) pyrazinecarboxamides: Structure-activity relationships of a new class of inhibitors of neovascularization. ARVO Annual Spring Meeting, Sarasota, 1991, Invest Ophthalmol Vis Sci 32:4, 1991, p. 771.
 77. Alliegro MC, Alliegro MA, Brooks S, and Glaser BM: Amiloride inhibition of neovascularization in vitro. ARVO Annual Spring Meeting, Sarasota, 1991, Invest Ophthalmol Vis Sci 32:4, 1991, p. 1046.
 78. Varner HH, Jerdan JA, Gilliam KD, and Glaser BM: Oral amiloride inhibits neovascularization. ARVO Annual Spring Meeting, Sarasota, 1991, Invest Ophthalmol Vis Sci 32:4, 1991, p. 1046.
 79. Lansing MB, Jerdan JA, and Glaser BM: Effect on vessel growth of corneal implantation of amiloride and related analogs. ARVO Annual Spring Meeting, Sarasota, 1991, Invest Ophthalmol Vis Sci 32:4, 1991, p. 1300.
 80. Pena RA, Jerdan JA, Glaser BM: Effects of TGF- β_1 , TGF- β_2 , and TGF- β neutralizing antibodies on fibroblast-induced collagen gel contraction: Implications for proliferative vitreoretinopathy. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 33:4, 1992, p. 859.
 81. Newell SW, Jerdan JA, Glaser BM: Retinal cryopexy induced elevation of intravenous level of transforming growth factor beta, type 2. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 33:4, 1992, p. 859.
 82. Lansing MB, Liss H, Glaser BM, Gordon AJ, Pena RA, Sjaarda RN, Thompson JT: The effect of pars plana vitrectomy and transforming growth factor beta-2 without epiretinal membrane peeling on full-thickness macular holes. ARVO Annual Spring Meeting,

- Sarasota, 1992. Invest Ophthalmol Vis Sci 33:4, 1992, p. 899.
83. Sjaarda RN, Glaser BM, Kuppermann BD, Michels RG: Pars plana vitrectomy and fluid-gas exchange for stage 2 macular holes. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 33:4, 1992, p. 899.
 84. Nonaka T, Jerdan JA, Ramsey CL, Glaser BM: Plasminogen activator inhibitor-1 (PAI-1) release by cultured human retinal pigment epithelial (RPE) cells. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 33:4, 1992, p. 910.
 85. Varner HH, Cairns N, Cragoe Jr. EJ, Dyer KD, Glaser BM: N-(diaminomethylene) pyrazinecarboxamide inhibitors of neovascularization: Contributions to uPA inhibition of guanidino and 3-amino moieties. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 33:4, 1992, p. 1080.
 86. Jerdan JA, Gilliam KD, Ramsey CL, Glaser BM: Antibodies against urokinase-type plasminogen activator (uPA) inhibit corneal neovascularization. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 33:4, 1992, p. 1088.
 87. Alliegro MA, Dyer KD, Glaser BM, Alliegro MC: Effects of amiloride on cell-bound vs. soluble uPA, and neovascularization in vitro. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 33:4, 1992, p. 1089.
 88. Pena RA, Nonaka T, Jerdan JA, Glaser BM: Effects of DGEA tetrapeptide on collagen gel contraction. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 34:4, 1993, p. 950.
 89. Gordon LW, Glaser BM, Thompson JT, Sjaarda RN: Progression to full-thickness macular hole in spite of complete posterior vitreous detachment. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 34:4, 1993, p. 990.
 90. Klein BR, Hiner CJ, Glaser BM, Murphy RP, Sjaarda RN, Thompson JT: Fluorescein angiographic and fundus photographic characteristics of pseudoholes of the macula in eyes with epiretinal membranes. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 34:4, 1993, p. 990.
 91. Sjaarda RN, Frank DA, Thompson JT, Glaser BM, Murphy RP: Assessment of pre & post-operative visual function with kinetic microperimetry using the scanning laser ophthalmoscope. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 34:4, 1993, p. 991.
 92. Smiddy WE, Glaser BM, Thompson JT, Sjaarda RN, Flynn HW, Jr., Hanham A, Murphy RP: Transforming growth factor beta-2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 34:4, 1993, p. 991.
 93. Thompson JT, Glaser BM, Sjaarda RN: Progressive nuclear sclerosis and visual acuity after pars plana vitrectomy and TGF beta-2 for full-thickness macular holes. ARVO

- Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 34:4, 1993, p. 991.
94. Murphy RP, Flower RW, Glaser BM, Sjaarda RN, Thompson JT, Hiner CJ: Indocyanine green angiographic studies of occult choroidal neovascularization. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 34:4, 1993, p. 1134.
 95. Hiner CJ, Murphy RP, Glaser BM, Sjaarda RN, Thompson JT: A grading protocol for the photographic characteristics of full thickness macular holes. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 34:4, 1993, p. 1167.
 96. Nonaka T, Pena RA, Jerdan JA, Glaser BM: Fibroblast and retinal pigment epithelial (RPE) cell attachment is inhibited by antibodies to integrin. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 34:4, 1993, p. 1205.
 97. Ie D, Glaser BM, Gordon LW, Ramsey CL, Jerdan JA, Pena RA: Transforming growth facto-beta 2 levels increase following retinal laser photocoagulation. ARVO Annual Spring Meeting, Sarasota, 1992. Invest Ophthalmol Vis Sci 34:4, 1993, p. 1440.
 98. Hiner CJ, Murphy RP, Glaser BM, Sjaarda RN, Thompson JT: A Comparison of Standard Indocyanine Green Videoangiographic Patterns to Standard Fluorescein Angiographic Patterns. ARVO Annual Spring Meeting, Sarasota, 1994. Invest Ophthalmol Vis Sci 35(4):1501, 1994.
 99. Murphy RP, Hiner CJ, Pappas SS, Jr., Thompson JT, Sjaarda RN, Glaser BM: Persistence of Choroidal Neovascularization (CNV) in Age-Related Macular Degeneration (AMD) Following Photocoagulation Treatment. ARVO Annual Spring Meeting, Sarasota, 1994. Invest Ophthalmol Vis Sci 35(4):1564, 1994.
 100. Smiddy WE, Sjaarda RN, Glaser BM, Flynn HW, Jr., Thompson JT, Hanham A: Vitrectomy and TGF- β 2 After Failed Macular Hole Surgery. ARVO Annual Spring Meeting, Sarasota, 1994. Invest Ophthalmol Vis Sci 35(4):1579, 1994.
 101. Sjaarda RN, Thompson JT, Glaser BM, Hanham A, Murphy RP: Iatrogenic Retinal Breaks Complicating Pars Plana Vitrectomy for Macular Hole. ARVO Annual Spring Meeting, Sarasota, 1994. Invest Ophthalmol Vis Sci 35(4):1580, 1994.
 102. Thompson JT, Smiddy WE, Glaser BM, Sjaarda RN, Flynn HW, Jr., Hanham A, Murphy RP: Intraocular Gas Tamponade Duration and Success of Macular Hole Treatment by Vitrectomy and TGF β 2. ARVO Annual Spring Meeting, Sarasota, 1994. Invest Ophthalmol Vis Sci 35(4):1712, 1994.
 103. Rubin JS, Sjaarda RN, Thompson JT, Pappas SS, Jr., Glaser BM: Results for Aggressive Surgical Management for Endophthalmitis. ARVO Annual Spring Meeting, Sarasota, 1994. Invest Ophthalmol Vis Sci 35(4):1994, 1994.
 104. Dean JM, Thompson JT, Ie D, Glaser BM, Murphy RP, Sjaarda RN: Indocyanine Green Angiographic Characteristics of Retinochoroidal inflammatory Disorders. ARVO Annual

- Spring Meeting, Sarasota, 1994. Invest Ophthalmol Vis Sci 35(4):2105, 1994.
105. Glaser BM, Murphy RP, Lakhanpal RR, Lin SB, Baudo TA: Identification and Treatment of Modulating Choroidal Vessels Associated with Occult Choroidal Neovascularization ARVO Annual Spring Meeting, Ft. Lauderdale, May 2000. Invest Ophthalmol Vis Sci 41(4):S320, 2000. Abstract nr 1687.
 106. Lakhanpal RR, Glaser BM, Murphy RP, Lin SB, Baudo TA: Observations and Characteristics of Polypoidal Choroidal Vasculopathy Using High-speed Indocyanine Green Angiography: A Pilot Study. ARVO Annual Spring Meeting, Ft. Lauderdale, May 2000. Invest Ophthalmol Vis Sci 41(4):B221, S163, 2000. Abstract nr 846.
 107. Baudo TA, Glaser BM, Lakhanpal RR, Lin SB, Gould DM, Murphy RP: Pilot Study to Examine the Outcomes Following Laser Treatment of Modulating Choroidal vessels Associated with Pigment Epithelia Detachments. ARVO Annual Spring Meeting, Ft. Lauderdale, May 2000. Invest Ophthalmol Vis Sci 41(4):B306, S179, 2000. Abstract nr 931.
 108. Glaser BM, Baudo TA, Velez G, Luu JK, Murphy RP: Feeder Treatment Vessel Treatment for Age-related Macular Degeneration (AMD) with Classic Choroidal Neovascularization (CNV). ARVO Annual Spring Meeting, Ft. Lauderdale. Invest Ophthalmol Vis Sci 42(4):B556, S231, 2001. Abstract nr 1243.
 109. Murphy RP, Lin SB, Glaser BM: Feeder Vessel Treatment for Age-related Macular Degeneration (AMD) with Subfoveal fibrovascular Choroidal Neovascularization (CNV). ARVO Annual Spring Meeting, Ft. Lauderdale, April 2001. Invest Ophthalmol Vis Sci 42(4):B557, S231, 2001. Abstract nr 1244.
 110. Luu JK, Baudo TA, Velez G, Murphy RP, Glaser, BM: Internal Tamponade Without tPA for the Treatment of Submacular Hemorrhage in Age-related Macular Degeneration. ARVO Spring Meeting, Ft. Lauderdale, April 2001. Invest Ophthalmol Vis Sci 42(4):B577, S234, 2001. Abstract nr 1264.
 111. Velez G, Baudo TA, Luu JK, Murphy RP, Glaser BM: High Speed ICG angiographic Characterization of Feeder Vessels to Choroidal Neovascularization Associated with Ocular Inflammatory Disease. ARVO Annual Spring Meeting, Ft. Lauderdale, April 2001. Invest Ophthalmol Vis Sci 42(4):B553, S230, 2001. Abstract nr 1240.
 112. Baudo TA, Velez G, Luu JK, Murphy RP, Glaser BM: Incidence of Predominantly Classic Choroidal Neovascular Membranes (CNV) in Exudative Age Related Macular Degeneration (AMD): Percentage of New Patients Eligible for Photodynamic therapy with Verteporfin. ARVO Annual Spring Meeting, Ft. Lauderdale, May 2001. Invest Ophthalmol Vis Sci 42(4):B610, S438, 2001. Abstract nr 2360.
 113. Johnson TM, Luu JK, Glaser BM: Micropulse Laser Modulation of Retinal Choroidal Anastomoses in Exudative Macular Degeneration. Invest Ophthalmol Vis Sci. 2002 43: E-Abstract 2506.

114. Luu, JK, Baudo TA, Glaser, BM: Feeder Vessel Treatment of recurrent Choroidal Neovascularization (CNV). Invest Ophthalmol Vis Sci. 2002 43: E-Abstract 2510.
115. Tuller RE, Glaser BM, Luu JK: Feeder Vessel (FV) Treatment of Choroidal Neovascularization (CNV) with Sub-tenon's Corticosteroid Injection as Adjuvant therapy. Invest Ophthalmol Vis Sci. 2002 43: E-Abstract 2513.
116. Roh ML, Glaser BM: Feeder Treatment of occult with no Classic Choroidal Neovascularization in Age-related Macular Degeneration. Invest Ophthalmol Vis Sci. 2003 44: E-Abstract 1776.
117. Han M, Luu, JK, Glaser, BM: Formation of Choroidal Venous Anastomosis after Radial Optic Neurotomy for Central Retinal Vein Occlusion. Invest Ophthalmol Vis Sci. 2003 44: E-Abstract 4046.
118. Winslow PL, Glaser BM: Optical Coherence Tomography and Outer Layer Reflectivity in the Evaluation of Surgically closed Idiopathic Macular Holes in the Extended Postoperative Period. Invest Ophthalmol Vis Sci. 2003 44: E-Abstract 4904.
119. Johnson TM, Glaser BM: High Speed ICG Guided Focal Laser Treatment of Retinal Angiomatous Proliferations. Invest. Ophthalmol. Vis. Sci. 2003 44: E-Abstract 5034.
120. Johnson TM, Glaser, BM: Flexible Rake for Removal of Epiretinal Membranes. Invest. Ophthalmol. Vis. Sci. 2005 46: E-Abstract 5518.
121. Stephens, JN, Johnson, TM, Glaser, BM: High Speed ICG Evaluation of Central Serous Retinopathy. Invest. Ophthalmol. Vis. Sci. 2005 46: E-Abstract 4062.
122. Vaughn, CW, Johnson, TM, Glaser, BM: Assessment of Macular Features Differentiating Macular Pseudohole From Idiopathic Epiretinal Membrane Using Optical Coherence Tomography. Invest. Ophthalmol. Vis. Sci. 2005 46: E-Abstract 1575.
123. Glaser, BM, Liotta, LA, Espina, V., Zhou, W, Camerini, S, Polci, ML, Petricoin, EF, Johnson, TM, Djafari, V and Kaplan, JA: application of Proteomic analysis to Characterize the Molecular pathways of the Vitreous and Retina in Health and Disease. Invest. Ophthalmol. Vis. Sci. 2006 47: E-Abstract 4865.
124. Barzideh, N, Glaser, BM and Djafari, V: Microperimetry is an Effective Test for Diagnosing Early Scotomas Secondary to hydroxychloroquine Maculopathy. Invest. Ophthalmol. Vis. Sci. 2006 47: E-Abstract 3811.
125. Johnson, TM and Glaser, BM: Anterior Subtenon Triamcinolone Injection for Management of Macular Edema Secondary to Retinal Vascular Disease. Invest. Ophthalmol. Vis. Sci. 2006 47: E-Abstract 4243.